A Reversal for Medicure Inc Is Not Near. The Stock Reaches 52-Week High Today

 A Reversal for Medicure Inc Is Not Near. The Stock Reaches 52 Week High Today

The stock of Medicure Inc (CVE:MPH) hit a new 52-week high and has $14.59 target or 87.00% above today’s $7.80 share price. The 8 months bullish chart indicates low risk for the $125.33M company. The 1-year high was reported on Nov, 18 by Barchart.com. If the $14.59 price target is reached, the company will be worth $109.04 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 113,961 shares traded hands or 589.63% up from the average. Medicure Inc (CVE:MPH) has risen 6.00% since October 19, 2016 and is uptrending. It has outperformed by 1.57% the S&P500.

More important recent Medicure Inc (CVE:MPH) news were published by: Streetinsider.com which released: “Medicure (MCUJF) Unit to Acquire Majority Stake in Apicore” on November 18, 2016, also Midasletter.com published article titled: “S&P/TSX Venture Composite Index Movers: GoldMoney Inc., Medicure Inc …”, Seekingalpha.com published: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” on February 17, 2016. More interesting news about Medicure Inc (CVE:MPH) was released by: Seekingalpha.com and their article: “FDA rejects Medicure’s application for expanded use of Aggrastat” with publication date: July 08, 2016.

Medicure Inc. is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The company has a market cap of $125.33 million. The Firm operates in the biopharmaceutical industry segment. It has a 27.49 P/E ratio. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc.

MPH.V Company Profile

Medicure Inc. (Medicure), incorporated on February 23, 2000, is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The Firm operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc. The Firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment